VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. O'Shaughnessy on Negative TNBC Iniparib Results

Joyce A. OShaughnessy, MD
Published: Tuesday, Aug 23, 2011

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that iniparib's mechanism of action (MOA) is still under intensive study and has been under examination since the drug was first discovered.

Despite its recent negative triple negative breast cancer (TNBC) trial results O'Shaughnessy believes iniparib will become interesting once again. She describes that in a physiological concentration you do no inhibit PARP but in higher concentrations inhibition does occur. She believes that once the MOA is fully understood more options will be available.

Other trials are currently underway examining iniparib; options are becoming clear, such as its single agent use in BRCA2 mutated pancreatic cancer. It is still being investigated in TNBC, which O'Shaughnessy believes is still too broad of a category. A subset of patients in the TNBC trial demonstrated a benefit to the drug; trials still need to be conducting to pinpoint this subset of patients.
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that iniparib's mechanism of action (MOA) is still under intensive study and has been under examination since the drug was first discovered.

Despite its recent negative triple negative breast cancer (TNBC) trial results O'Shaughnessy believes iniparib will become interesting once again. She describes that in a physiological concentration you do no inhibit PARP but in higher concentrations inhibition does occur. She believes that once the MOA is fully understood more options will be available.

Other trials are currently underway examining iniparib; options are becoming clear, such as its single agent use in BRCA2 mutated pancreatic cancer. It is still being investigated in TNBC, which O'Shaughnessy believes is still too broad of a category. A subset of patients in the TNBC trial demonstrated a benefit to the drug; trials still need to be conducting to pinpoint this subset of patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x